DEA Fine Tunes Power of Attorney and DEA-222 Requirements

Key Takeaways

• Only registrants, officers, or partners can execute POAs
• POA signers must also be authorized DEA‑222 signatories
• Prior “last applicant” signing authority is eliminated
• Obsolete triplicate DEA‑222 transition clause removed
• Amendment effective immediately, requiring compliance updates

Summary

On March 20, 2026, the DEA issued a technical amendment to its 2019 final rule that clarifies who may execute and revoke Power of Attorney documents for DEA Form 222 and who may sign the form itself. The amendment aligns 21 C.F.R. § 1305.05(c) and § 1305.05(e) with the earlier requirement that only the registrant, an officer, or a partnership partner can authorize POAs, eliminating the previous loophole allowing the last registration applicant to sign. It also removes the obsolete transition provision for triplicate DEA‑222 forms, which had been phased out in 2021. The rule takes effect immediately.

Pulse Analysis

S. Official Order Form for Schedule I and II controlled substances, has been a cornerstone of pharmaceutical and research supply chains since its inception. In 2019 the agency introduced a single‑sheet version to replace the cumbersome triplicate format, granting registrants a two‑year transition window that ended in October 2021. R.

05(d)(1): the registrant themselves, an officer of a corporate entity, or a partner of a partnership. This eliminates the outdated provision that permitted the individual who signed the most recent registration application to act as a POA signatory. \n\nFor businesses that handle Schedule I and II substances, the amendment triggers immediate compliance actions.

Companies must review internal delegation matrices, update POA documentation, and train designated officers or partners on the new signing protocols. Failure to align with the revised regulations could result in enforcement actions, fines, or suspension of ordering privileges. Moreover, the removal of the obsolete triplicate transition clause simplifies record‑keeping, allowing firms to focus on a single, standardized form. In a market where regulatory precision directly impacts supply continuity, the DEA’s clarification reinforces accountability and mitigates risk across the controlled‑substance ecosystem.